Cytochrome P450 2D6 Antibody - #DF4758

(1)   (5)  
Product: Cytochrome P450 2D6 Antibody
Catalog: DF4758
Description: Rabbit polyclonal antibody to Cytochrome P450 2D6
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Sheep
Mol.Wt.: 56 KD; 56kD(Calculated).
Uniprot: P10635
RRID: AB_2837112

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:1000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Sheep(82%)
Clonality:
Polyclonal
Specificity:
Cytochrome P450 2D6 Antibody detects endogenous levels of total Cytochrome P450 2D6.
RRID:
AB_2837112
Cite Format: Affinity Biosciences Cat# DF4758, RRID:AB_2837112.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

CPD6; CYP2D; CYP2D6; CYP2D7AP; CYP2D7BP; CYP2D7P2; CYP2D8P2; CYP2DL1; CYPIID6; Cytochrome P450 DB1; Cytochrome P450 family 2 subfamily D polypeptide 6; Debrisoquine 4 hydroxylase; Flavoprotein linked monooxygenase; Microsomal monooxygenase; P450 DB1; P450C2D; P450DB1; Xenobiotic monooxygenase;

Immunogens

Immunogen:
Uniprot:

P10635(CP2D6_HUMAN) >>Visit HPA database.

Gene(ID):
CYP2D6(1565)
Sequence:
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQLRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVFLARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDKAVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKVLRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVADLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVIHEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHFLDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGVFAFLVSPSPYELCAVPR

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Sheep
82
Xenopus
73
Pig
0
Horse
0
Bovine
0
Dog
0
Zebrafish
0
Chicken
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P10635 As Substrate

Site PTM Type Enzyme
Y124 Phosphorylation
S135 Phosphorylation
S217 Phosphorylation

Research Backgrounds

Function:

A cytochrome P450 monooxygenase involved in the metabolism of fatty acids, steroids and retinoids. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 20-hydroxyeicosatetraenoic acid ethanolamide (20-HETE-EA) and 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling. Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis. Catalyzes the oxidative transformations of all-trans retinol to all-trans retinal, a precursor for the active form all-trans-retinoic acid. Also involved in the oxidative metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.

Subcellular Location:

Endoplasmic reticulum membrane>Peripheral membrane protein. Microsome membrane>Peripheral membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Family&Domains:

Belongs to the cytochrome P450 family.

Research Fields

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Metabolism > Xenobiotics biodegradation and metabolism > Metabolism of xenobiotics by cytochrome P450.

· Metabolism > Xenobiotics biodegradation and metabolism > Drug metabolism - cytochrome P450.

· Organismal Systems > Nervous system > Serotonergic synapse.

References

1). A combination of pirfenidone and TGF-β inhibition mitigates cystic echinococcosis–associated hepatic injury. PARASITOLOGY (PubMed: 33583470) [IF=2.4]

Application: IF/ICC    Species: mice    Sample: liver tissues

Fig. 6. Combination of pirfenidone and SB525334 reduced the senescence of hepatocytes in mice with CE. (A) Both pirfenidone and combined medication potentially reduced the expression of p16, p21 and p53 (markers of hepatocyte ageing). However, SB525334 could only reduce the expression of p21 and p53. (B) and (C) Immunofluorescence showing that combined medication could reduce the expression of p21 and p53 more effectively compared to both individual drugs and controls. (D) SA-β-Gal staining revealing that combined treatment could more effectively alleviate senescence in hepatocytes compared to the individual drugs. All the images were obtained from a microscopic imaging system at 40× magnification. Data are representative of one of three independent experiments (n = 3–4 mice per group). One-way ANOVA was used for analysis in (A), bars represent the mean ± S.E.M. (ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001)

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.